Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)

NCT00511121 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: STI571 and PEG INTRON

Sponsor

University of Bologna

Collaborators

[object Object]
[object Object]